Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK Population-based Patient Cohort

Overview

Journal Int J Epidemiol

Specialty Public Health

Date 2018 Apr 5

PMID 29618056

Citations 34

Authors

Alexandra Smith

Debra Howell

Simon Crouch

Dan Painter

John Blase

Han-I Wang

Ann Hewison

Timothy Bagguley

Simon Appleton

Sally Kinsey

Cathy Burton

Russell Patmore

Eve Roman

Affiliations

Soon will be listed here.

Citing Articles

A 16-week progressive exercise training intervention in treatment-naïve chronic lymphocytic leukaemia: a randomised-controlled pilot study.

Brown F, Oliver R, Eddy R, Causer A, Emery A, Collier-Bain H Front Oncol. 2024; 14:1472551.

PMID: 39703835 PMC: 11655450. DOI: 10.3389/fonc.2024.1472551.

Information preferences of patients with chronic blood cancer: A qualitative investigation.

Howell D, McCaughan D, Smith A, Patmore R, Roman E PLoS One. 2024; 19(8):e0293772.

PMID: 39163402 PMC: 11335164. DOI: 10.1371/journal.pone.0293772.

The National Swedish Lymphoma Register - a systematic validation of data quality.

Smedby K, Eloranta S, Wasterlid T, Falini V, Jerlstrom U, Ellin F Acta Oncol. 2024; 63:563-572.

PMID: 38988133 PMC: 11332524. DOI: 10.2340/1651-226X.2024.40431.

Genetically determined telomere length as a risk factor for hematological malignancies: evidence from Mendelian randomization analysis.

Fang T, Zhang Z, Ren K, Zou L Aging (Albany NY). 2024; 16(5):4684-4698.

PMID: 38451181 PMC: 10968690. DOI: 10.18632/aging.205625.

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.

Ghesquieres H, Cherblanc F, Belot A, Micon S, Bouabdallah K, Esnault C Blood Adv. 2023; 8(2):296-308.

PMID: 37874913 PMC: 10824688. DOI: 10.1182/bloodadvances.2023010798.

References

Al-Refaie W, Vickers S, Zhong W, Parsons H, Rothenberger D, Habermann E . Cancer trials versus the real world in the United States. Ann Surg. 2011; 254(3):438-42. DOI: 10.1097/SLA.0b013e31822a7047. View

Smith A, Painter D, Howell D, Evans P, Smith G, Patmore R . Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014; 4(1):e004266. PMC: 3902525. DOI: 10.1136/bmjopen-2013-004266. View

Roman E, Smith A, Appleton S, Crouch S, Kelly R, Kinsey S . Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. Cancer Epidemiol. 2016; 42:186-98. PMC: 4911595. DOI: 10.1016/j.canep.2016.03.011. View

Freemantle N, Marston L, Walters K, Wood J, Reynolds M, Petersen I . Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013; 347:f6409. DOI: 10.1136/bmj.f6409. View

Elting L, Cooksley C, Bekele B, Frumovitz M, Avritscher E, Sun C . Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006; 106(11):2452-8. DOI: 10.1002/cncr.21907. View

van de Water W, Kiderlen M, Bastiaannet E, Siesling S, Westendorp R, van de Velde C . External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer. J Natl Cancer Inst. 2014; 106(4):dju051. DOI: 10.1093/jnci/dju051. View

Howell D, Wang H, Smith A, Howard M, Patmore R, Roman E . Place of death in haematological malignancy: variations by disease sub-type and time from diagnosis to death. BMC Palliat Care. 2013; 12(1):42. PMC: 4175093. DOI: 10.1186/1472-684X-12-42. View

Mariotto A, Yabroff K, Shao Y, Feuer E, Brown M . Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103(2):117-28. PMC: 3107566. DOI: 10.1093/jnci/djq495. View

Janson M, Edlund G, Kressner U, Lindholm E, Pahlman L, Skullman S . Analysis of patient selection and external validity in the Swedish contribution to the COLOR trial. Surg Endosc. 2008; 23(8):1764-9. DOI: 10.1007/s00464-008-0203-7. View

10.

Allemani C, Weir H, Carreira H, Harewood R, Spika D, Wang X . Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2014; 385(9972):977-1010. PMC: 4588097. DOI: 10.1016/S0140-6736(14)62038-9. View

11.

Wang H, Smith A, Aas E, Roman E, Crouch S, Burton C . Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2016; 18(2):255-267. PMC: 5313581. DOI: 10.1007/s10198-016-0775-4. View

12.

Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G . Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. Br J Haematol. 2017; 177(1):67-71. PMC: 5396308. DOI: 10.1111/bjh.14513. View

13.

Mohd Noor A, Sarker D, Vizor S, McLennan B, Hunter S, Suder A . Effect of patient socioeconomic status on access to early-phase cancer trials. J Clin Oncol. 2012; 31(2):224-30. DOI: 10.1200/JCO.2012.45.0999. View

14.

Rothwell P . External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005; 365(9453):82-93. DOI: 10.1016/S0140-6736(04)17670-8. View

15.

McCaughan D, Roman E, Smith A, Garry A, Johnson M, Patmore R . Determinants of hospital death in haematological cancers: findings from a qualitative study. BMJ Support Palliat Care. 2017; 8(1):78-86. PMC: 5867428. DOI: 10.1136/bmjspcare-2016-001289. View

16.

de Oliveira C, Pataky R, Bremner K, Rangrej J, Chan K, Cheung W . Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016; 16(1):809. PMC: 5070134. DOI: 10.1186/s12885-016-2835-7. View

17.

Cogle C, Craig B, Rollison D, List A . Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011; 117(26):7121-5. PMC: 3143554. DOI: 10.1182/blood-2011-02-337964. View

18.

Wang H, Aas E, Howell D, Roman E, Patmore R, Jack A . Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model. Value Health. 2014; 17(2):205-14. DOI: 10.1016/j.jval.2013.12.007. View

19.

Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E . Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015; 39(6):1103-12. PMC: 4676192. DOI: 10.1016/j.canep.2015.08.015. View

20.

Hunt K, Shlomo N, Addington-Hall J . End-of-life care and achieving preferences for place of death in England: results of a population-based survey using the VOICES-SF questionnaire. Palliat Med. 2013; 28(5):412-21. DOI: 10.1177/0269216313512012. View